杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/06/26 | 1,705 | 1,717 | 1,697 | 1,714 | +8 | +0.5% | 93,600 |
| 2024/06/25 | 1,722 | 1,722 | 1,703 | 1,706 | -11 | -0.6% | 204,700 |
| 2024/06/24 | 1,715 | 1,720 | 1,704 | 1,717 | +20 | +1.2% | 91,300 |
| 2024/06/21 | 1,703 | 1,718 | 1,693 | 1,697 | -12 | -0.7% | 208,800 |
| 2024/06/20 | 1,693 | 1,713 | 1,693 | 1,709 | +9 | +0.5% | 91,300 |
| 2024/06/19 | 1,697 | 1,701 | 1,686 | 1,700 | +9 | +0.5% | 71,300 |
| 2024/06/18 | 1,676 | 1,694 | 1,676 | 1,691 | -4 | -0.2% | 61,100 |
| 2024/06/17 | 1,685 | 1,695 | 1,674 | 1,695 | +12 | +0.7% | 72,500 |
| 2024/06/14 | 1,690 | 1,698 | 1,680 | 1,683 | +2 | +0.1% | 89,200 |
| 2024/06/13 | 1,685 | 1,687 | 1,675 | 1,681 | -11 | -0.7% | 47,700 |
| 2024/06/12 | 1,699 | 1,705 | 1,688 | 1,692 | -2 | -0.1% | 67,400 |
| 2024/06/11 | 1,687 | 1,699 | 1,683 | 1,694 | +4 | +0.2% | 64,900 |
| 2024/06/10 | 1,669 | 1,693 | 1,664 | 1,690 | +33 | +2% | 87,800 |
| 2024/06/07 | 1,655 | 1,662 | 1,646 | 1,657 | +3 | +0.2% | 109,000 |
| 2024/06/06 | 1,674 | 1,677 | 1,648 | 1,654 | -20 | -1.2% | 187,700 |
| 2024/06/05 | 1,686 | 1,688 | 1,664 | 1,674 | -15 | -0.9% | 205,000 |
| 2024/06/04 | 1,703 | 1,703 | 1,687 | 1,689 | -26 | -1.5% | 156,700 |
| 2024/06/03 | 1,716 | 1,731 | 1,713 | 1,715 | ±0 | ±0% | 51,900 |
| 2024/05/31 | 1,720 | 1,729 | 1,712 | 1,715 | -1 | -0.1% | 306,100 |
| 2024/05/30 | 1,695 | 1,716 | 1,691 | 1,716 | +13 | +0.8% | 57,900 |
| 2024/05/29 | 1,705 | 1,717 | 1,699 | 1,703 | -2 | -0.1% | 38,500 |
| 2024/05/28 | 1,710 | 1,712 | 1,700 | 1,705 | -2 | -0.1% | 33,100 |
| 2024/05/27 | 1,702 | 1,708 | 1,695 | 1,707 | +5 | +0.3% | 61,300 |
| 2024/05/24 | 1,690 | 1,705 | 1,690 | 1,702 | +14 | +0.8% | 103,600 |
| 2024/05/23 | 1,697 | 1,709 | 1,687 | 1,688 | -9 | -0.5% | 78,800 |
| 2024/05/22 | 1,708 | 1,715 | 1,697 | 1,697 | -17 | -1% | 107,500 |
| 2024/05/21 | 1,726 | 1,735 | 1,713 | 1,714 | -1 | -0.1% | 70,400 |
| 2024/05/20 | 1,712 | 1,716 | 1,705 | 1,715 | +3 | +0.2% | 84,400 |
| 2024/05/17 | 1,710 | 1,716 | 1,703 | 1,712 | +2 | +0.1% | 107,100 |
| 2024/05/16 | 1,725 | 1,725 | 1,705 | 1,710 | -18 | -1% | 86,100 |
| 2024/05/15 | 1,735 | 1,765 | 1,724 | 1,728 | +8 | +0.5% | 127,300 |
| 2024/05/14 | 1,750 | 1,754 | 1,720 | 1,720 | -33 | -1.9% | 131,400 |
| 2024/05/13 | 1,795 | 1,795 | 1,733 | 1,753 | -76 | -4.2% | 138,600 |
| 2024/05/10 | 1,831 | 1,832 | 1,820 | 1,829 | +7 | +0.4% | 34,500 |
| 2024/05/09 | 1,819 | 1,834 | 1,809 | 1,822 | +22 | +1.2% | 31,800 |
| 2024/05/08 | 1,837 | 1,837 | 1,800 | 1,800 | -35 | -1.9% | 34,200 |
| 2024/05/07 | 1,839 | 1,840 | 1,829 | 1,835 | -4 | -0.2% | 30,500 |
| 2024/05/02 | 1,836 | 1,842 | 1,829 | 1,839 | +1 | +0.1% | 22,400 |
| 2024/05/01 | 1,826 | 1,843 | 1,821 | 1,838 | -1 | -0.1% | 28,900 |
| 2024/04/30 | 1,828 | 1,839 | 1,816 | 1,839 | +11 | +0.6% | 52,600 |
| 2024/04/26 | 1,810 | 1,828 | 1,801 | 1,828 | +18 | +1% | 84,900 |
| 2024/04/25 | 1,825 | 1,825 | 1,805 | 1,810 | +3 | +0.2% | 55,500 |
| 2024/04/24 | 1,812 | 1,825 | 1,801 | 1,807 | -5 | -0.3% | 73,700 |
| 2024/04/23 | 1,808 | 1,813 | 1,797 | 1,812 | +7 | +0.4% | 54,600 |
| 2024/04/22 | 1,791 | 1,810 | 1,791 | 1,805 | +28 | +1.6% | 56,900 |
| 2024/04/19 | 1,793 | 1,795 | 1,764 | 1,777 | -17 | -0.9% | 71,900 |
| 2024/04/18 | 1,790 | 1,801 | 1,785 | 1,794 | +7 | +0.4% | 37,900 |
| 2024/04/17 | 1,795 | 1,798 | 1,778 | 1,787 | -16 | -0.9% | 48,800 |
| 2024/04/16 | 1,812 | 1,817 | 1,795 | 1,803 | -25 | -1.4% | 45,700 |
| 2024/04/15 | 1,812 | 1,830 | 1,807 | 1,828 | +2 | +0.1% | 50,500 |
101～
150
件表示中 / 3585件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 149,100円 | +3.2% | +4.5% | 3.49% | 17.13倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| ゼリア新薬 | 222,100円 | +13.6% | +29.2% | 2.07% | 11.52倍 | 1.11倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
| ネクセラファーマ | 113,700円 | +197.7% | - | 0.00% | 46.47倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| ＪＣＲファーマ | 69,600円 | -3.7% | -36.7% | 2.87% | 22.92倍 | 1.50倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
| 栄研化 | 210,100円 | +0.4% | -8.4% | 2.52% | 27.77倍 | 1.58倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム
